Abstract:Abstract Background: Hepatitis B surface antigen (HBsAg) and viral load are important clinical indicators for patients with chronic hepatitis B (CHB) infection treated with antiviral therapy. Few studies have evaluated viral sequence biomarkers predicting the risk of hepatocellular carcinoma (HCC) in the stage, which show a low serological response (HBsAg <100 IU/ml) and high viral levels (HBV DNA >2,000 IU/ml). Additionally, point mutations within the pre S/S regions of HBsAg have frequently been reported to be associated with diagnostic failure, vaccine escape and immunotherapy escape. However, the prevalence of escape mutations with low levels of HBsAg (<100 IU/ml) in inactive HBsAg carriers has not been systematically studied within the past decade. Methods: This study aims to determine the trend of the biological prevalence of escape mutations within the pre S/S regions of special model of inactive CHB infection. Increased diversity over the complete HBV genome at baseline was associated with evolutionary characteristics. We used Sanger sequencing, quantitative HBV serology (HBeAg and HBsAg) and liver function index (aspartate alanine aminotransferase, ALT; alanine aminotransferase, AST) to identify whether HBV genome sequences are associated with the serological response to long-term host immunity in special inactive CHB infection.Results: Compared to HBV in HCC, HBV sequencing analysis of 28 LR/RA CHB patients with genotypes B and C showed higher genetic diversity among four ORFs, but the two groups presented similar selective pressure. Seven positive selection sites in the pre-S1 region are potentially associated with immune evasion. These mutations in the pre-S/S region might be associated with the HCC phenotype of low HBsAg expression, with the P region possibly impacting high viral loads.Conclusion: According to the results of this study, LR/RA CHB is characterized by not only genetic diversity but also positive evolutionary pressure within the pre-S/S regions. Increased viral diversity across the HBV genome is also associated with low levels of HBsAg. In conclusion, the cumulative evolutionary changes in the HBV pre-S/S regions that facilitate immune evasion should be monitored individually. Due to the similarity of evolutionary characteristics in HCC, low serological responses and high viremia may be associated with the risk of HCC.

ELISA Differential Analysis:A Novel Convenient and Practical Method for Detecting Immune Escape Mutant HBsAg

Determination of Low Level HBsAg in Serum by Microparticle Enzyme Immunoassay.

Determination of Low Level HBsAg in Serum by MEIA

[Relationship between the quantitative results of HBV DNA and HBV markers (HBV M) in population with low-level HBsAg].

Evaluation of methods for confirming the weak-reactive results of HBsAg in serum

Analysis of suspicious results of serum HBV DNA detected by fluorescence quantitative PCR

Novel double-antigen sandwich immunoassay for human hepatitis B core antibody.

A new vaccine escape mutant of hepatitis B virus causes occult infection.

Comparison of the results for three automated immunoassay systems in determining serum HBV markers.

Comparison study and analysis of detecting HBsAb using ECLIA and ELISA

Development of Excluded ELISA and Its Application in the Detection of HBsAg in Sera with Hepatitis B Virus Infection

Evaluation of Domestic Qualitative Reagents for Detecting Anti-Hbs in Assessing the Immunity to Hepatitis B Virus

Factors affecting immunodetection of hepatitis B surface antigen recombinant mutants

Multicentre Evaluation of the Elecsys® Hepatitis B Surface Antigen II Assay for Detection of HBsAg in Comparison with Other Commercially Available Assays

Detection of low level HBsAg and its clinical significance

Sensitivity and specificity of 4 domestic ELISA kits for detection of hepatitis B virus markers

Comparative analysis of the difference between three methods in detecting HBV serum markers

[Comparison of results of two immunoassays for detection of hepatitis B surface antigen in pregnant women].

Evolutionary analysis of pre S/S mutations in HBeAg-negative chronic hepatitis B with HBsAg <100 IU/ml

Development of a two-site immuno-PCR assay for hepatitis B surface antigen